Background: To evaluate the CSF p-Tau181/Tau ratio to distinguish between the two main forms of frontotemporal lobar degeneration (FTLD): FTLD with TAR DNA-binding protein 43 (TDP-43) immunoreactive inclusions (FTLD-TDP) and FTLD with Tau inclusions (FTLD-Tau). Methods: Differences in the CSF p-Tau/t-Tau ratio were examined in patients with predictable Tau (n=27, as affected by Progressive Supranuclear Palsy) and TDP-43 (n=22, as carriers of mutations within Granulin gene, C9orf72 or affected by FTD with motor neuron disease) neuropathology. Cut-off values were determined to achieve highest values of sensitvity and specificity according to ROC curve analysis. Cut-off values were applied to a second cohort of cases with unpredictable underlying neuropathology, including behavioural variant FTD (bvFTD, n=82), corticobasal degeneration (CBS, n=40), agrammatic variant of primary progressive aphasia (avPPA, n=16), amyotrophic lateral sclerosis (ALS, n=12), and synucleopathies (Dementia with Lewy bodies, multiple system atrophy, n=16), and healthy controls (HC, n=37). Results: FTLD-TDP cases had reduced levels of p-Tau, and the cut-off value of <0.1305 (p/t-Tau ratio) allowed to differentiate FTLD-TDP from FTLD-Tau with 92.6% sensitivity and 77.3% specificity. In non-TDP disease, such as synucleopathies, ratio score was within normal range in 68.8% of cases, whilst in TDP disease, such as ALS, predicted neuropathology in almost 70% of cases. A TDP-like p/t-Tau ratio was found in 51.2% bvFTD, with a distribution consistent with previous clinicopathologic studies in FTLD, in 25% of CBS, and in 43.8% of avPPA patients. HC had a ratio within normal range in 73% of cases. Conclusions: A reliable biomarker that accurately predicts the FTLD neuropathology is urgently needed in the prospect of disease-modifying therapies that target the underlying pathological process. A reduced CSF p/t-Tau ratio represents a viable and reproducible biomarker to correctly distinguish FTLD-TDP and FTLD-Tau. Detecting an on-going TDP or Tau pathological process in FTLD has several implications for defining distinctive therapeutic approaches, guiding genetic screening and helping in patients' selection in future clinical trials.

CSF p-Tau181/Tau ratio to distinguish FTLD-TDP from FTLD-Tau

Alessandro Padovani
;
Alberto Benussi;Barbara Borroni
2014-01-01

Abstract

Background: To evaluate the CSF p-Tau181/Tau ratio to distinguish between the two main forms of frontotemporal lobar degeneration (FTLD): FTLD with TAR DNA-binding protein 43 (TDP-43) immunoreactive inclusions (FTLD-TDP) and FTLD with Tau inclusions (FTLD-Tau). Methods: Differences in the CSF p-Tau/t-Tau ratio were examined in patients with predictable Tau (n=27, as affected by Progressive Supranuclear Palsy) and TDP-43 (n=22, as carriers of mutations within Granulin gene, C9orf72 or affected by FTD with motor neuron disease) neuropathology. Cut-off values were determined to achieve highest values of sensitvity and specificity according to ROC curve analysis. Cut-off values were applied to a second cohort of cases with unpredictable underlying neuropathology, including behavioural variant FTD (bvFTD, n=82), corticobasal degeneration (CBS, n=40), agrammatic variant of primary progressive aphasia (avPPA, n=16), amyotrophic lateral sclerosis (ALS, n=12), and synucleopathies (Dementia with Lewy bodies, multiple system atrophy, n=16), and healthy controls (HC, n=37). Results: FTLD-TDP cases had reduced levels of p-Tau, and the cut-off value of <0.1305 (p/t-Tau ratio) allowed to differentiate FTLD-TDP from FTLD-Tau with 92.6% sensitivity and 77.3% specificity. In non-TDP disease, such as synucleopathies, ratio score was within normal range in 68.8% of cases, whilst in TDP disease, such as ALS, predicted neuropathology in almost 70% of cases. A TDP-like p/t-Tau ratio was found in 51.2% bvFTD, with a distribution consistent with previous clinicopathologic studies in FTLD, in 25% of CBS, and in 43.8% of avPPA patients. HC had a ratio within normal range in 73% of cases. Conclusions: A reliable biomarker that accurately predicts the FTLD neuropathology is urgently needed in the prospect of disease-modifying therapies that target the underlying pathological process. A reduced CSF p/t-Tau ratio represents a viable and reproducible biomarker to correctly distinguish FTLD-TDP and FTLD-Tau. Detecting an on-going TDP or Tau pathological process in FTLD has several implications for defining distinctive therapeutic approaches, guiding genetic screening and helping in patients' selection in future clinical trials.
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11379/516470
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact